

**The discriminatory ability of analytical quality
control test methods: A comparison of test
results from different international monographs
of quinine sulfate tablets**

**C Britz
21656525
B.Sc (Hons) Pharmacology**

Dissertation submitted in *partial* fulfillment of the requirements
for the degree *Magister Scientiae* in *Pharmaceutics* at the
Potchefstroom Campus of the North-West University

Supervisor: Mr. Zak Perold
Co-supervisor: Dr. Marius Brits

November 2013

Acknowledgements

To El Sali (the God of my strength) all the glory.

I am grateful to the following persons and institutions for support during this study:

Zak Perold – thank you for your guidance, support and patience, it was invaluable. Not only were you good mentor, but also a good friend.

Dr Marius Brits – for fulfilling your duties as co-supervisor.

The North-West University, especially the School of Pharmacy for granting me the opportunity to obtain my M.Sc. degree.

Prof Jeanetta du Plessis (Director of Research, Unit for Drug Research and Development, NWU) – for financial support, encouragement and guidance.

Prof Banie Boneschans – for financial support, encouragement and guidance.

Dr Erna Swanepoel (RIIP[®]/CENQAM[®]) – thank you for allowing me the use of the facilities at the RIIP[®]/CENQAM[®].

My mother (EWD Britz) and father (LJ Britz) – for your endless support and love. You are the wind beneath my wings.

Stefan van Rooyen – there is just no words that are adequate to describe my deep love and gratitude for you. Thank you.

Prof Anita Wessels and Susan Lindeque – your help and guidance were invaluable.

To Tannie Bessie von Burick, Jacolien, Pieter, Elana and Carissa du Plooy and Vanessa and Eddie Lovering – thank you for your love, support and motivation.

Nicolene Lubbe - thank you for your love, support and motivation.

Engela Oosthuizen – thank you for technically editing my dissertation.

My friends, family and colleagues – to name you one by one is challenging because there are so many of you. I therefore want to express my heartfelt gratitude to each of you – thanks for your unwavering support.

Abstract

Malaria is a parasitic disease claiming one million lives worldwide annually. Unfortunately, malaria-endemic countries in need of good quality medicines are also overwhelmed with counterfeit or substandard medicine. This results in treatment inefficacy, resistance towards treatment and death. Counterfeit or substandard quinine sulfate tablets are known to have infiltrated the market, however at this point in time, treatment efficacy of quinine sulfate has fortunately not yet been significantly impaired by resistance, but immediate action is required to prevent it from becoming obsolete.

Validated analytical methods with justified specifications are effective in controlling the quality of medicines and to minimise the effect of poor quality medicines. Pharmacopoeia specifies analytical quality control procedures and accompanying specifications to standardise acceptable levels of product quality. Understandably, different monographs of different pharmacopoeias are developed by different independent laboratories and therefore their respective test procedures/specifications for the same FPP may differ from each other. Institutions such as the Pharmacopoeial Discussion Group (PDG) aim to harmonise pharmacopoeia in order to synchronise final outcomes.

This study evaluated the relevancy of differences in analytical procedures, results and specifications for quinine sulfate tablets set by the United States Pharmacopoeia (USP), British Pharmacopoeia (BP) and International Pharmacopoeia (*Ph.Int.*) in an aim to ensure that these different methods all provide with similar final outcomes and that they be effective in successfully evaluating the quality of quinine sulfate tablets. Four quinine sulfate tablet products were obtained from different manufacturers and were subjected to the tests of all three pharmacopoeia – BP, USP and *Ph.Int.*

The results from identification, assay and related substance testing concluded that the outcomes were the same between the pharmacopoeia despite their differences in techniques/procedures/specifications. The assay, identification and related substances methods and specifications set by each respective monograph were deemed appropriate to evaluate the quality of quinine sulfate tablets.

Even with differences in methodology, quantitative techniques and specifications, the USP and BP dissolution methods for quinine sulfate tablets shared the same final outcome at the first stage of dissolution, whereas none of the products achieved a compliant outcome using the *Ph.Int.* dissolution method.

Possible reasons for the poor dissolution (when using the *Ph.Int.* method) were identified and investigated. Investigation into the solubility of quinine sulfate found *the Ph.Int.* dissolution method conditions to be too stringent, as the solubility of quinine sulfate in phosphate buffer pH 6.8 (dissolution medium specified by the *Ph.Int.*) was found to be much less than in acidic media (as proposed by the BP and USP dissolution methods). Several adapted dissolution methods (called developmental studies) were investigated to serve as potential alternatives for the *Ph.Int.* dissolution method. The developmental studies investigated an alternative dissolution medium, agitation rates (50 rpm, 75 rpm, 100 rpm) and medium volumes (500 ml, 750 ml, 900 ml and 1000 ml). Developmental study 6 was proposed as an alternative dissolution method. Developmental study 6 stipulates the use of the same medium as the original *Ph.Int.* method, as it was deemed the medium of choice for its discriminatory ability. To address the impaired solubility of quinine sulfate in phosphate buffer, the medium volume and agitation were increased (in reference to the original method) to 900 ml and 100 rpm respectively. The same analytical quantitation technique (UV-Vis spectroscopy) is proposed for Developmental study 6. The newly proposed method provided with final outcomes comparable to that of the USP and BP, however having more discriminatory power than the USP and BP.

Keywords: quinine sulfate tablets, dissolution, malaria, pharmacopoeia, validated analytical methods, harmonisation

Uittreksel

Malaria is 'n parasitiese siekte wat jaarliks 'n miljoen lewens wêreldwyd eis. Malaria-endemiese lande wat goeie kwaliteit medisyne benodig, word ongelukkig oorstroom met medisyne wat vervals of substandaard is. Dit lei tot oneffektiewe behandeling, weerstand teen behandeling en die dood. Dit is bekend dat vervalste of substandaard kiniensulfaatablette die mark infiltreer het. Op hierdie tydstip is die behandelingseffektiwiteit van kiniensulfaat gelukkig nog nie beduidend deur weerstand belemmer nie, maar onmiddellike optrede is nodig om te voorkom dat dit uitgedien raak.

Gevalideerde analitiese metodes met geregverdigde spesifikasies is effektief om die kwaliteit van medisyne te beheer en om die uitwerking van swak gehalte medisyne te minimaliseer. Farmakopeë spesifiseer analitiese kwaliteitsbeheerprosedures en gepaardgaande spesifikasies om aanvaarbare vlakke van produkkwaliteit te standaardiseer. Dit is verstaanbaar dat verskillende monograwe van verskillende farmakopeë ontwikkel word deur verskillende onafhanklike laboratoriums en gevolglik mag hul onderskeie toetsprosedures/spesifikasies vir dieselfde finale farmaseutiese produk van mekaar verskil. Instellings soos die Pharmacopoeial Discussion Group (PDG) (Farmakopeë Besprekingsgroep) beoog om farmakopeë te harmoniseer sodat die eindresultaat gesinchroniseer kan wees.

Hierdie studie het die tersaaklikheid van verskille in analitiese prosedures, resultate en spesifikasies vir kiniensulfaatablette, soos gestel deur die United States Pharmacopoeia (USP), British Pharmacopoeia (BP) en International Pharmacopoeia (*Ph.Int.*) geëvalueer, met die doelwit om te verseker dat hierdie verskillende metodes almal dieselfde finale uitkomst bied en dat hulle effektief is om die kwaliteit van kiniensulfaatablette suksesvol te evalueer. Vier kiniensulfaatablet produkte is verkry van verskillende vervaardigers en is onderwerp aan die toetse van al drie farmakopeë – BP, USP en *Ph.Int.*

Die gevolgtrekking uit die resultate van toetsing van identifikasie, essai en verwante middels, was dat die uitkomst dieselfde was tussen die farmakopeë, ten spyte van die verskille in tegnieke/prosedures/spesifikasies. Die essai, identifikasie en verwante middel metodes en spesifikasies soos gestel deur elke onderskeie monograaf, is gereken om geskik te wees om die kwaliteit van kiniensulfaatablette te evalueer.

Selfs met verskille in metodologie, kwantitatiewe tegnieke en spesifikasies, het die USP en BP se dissolusiemetodes vir kiniensulfaatablette dieselfde finale uitkoms gehad by die eerste stadium van dissolusie, terwyl geen van die produkte 'n uitkoms gehad het wat aan die vereistes voldoen met gebruik van die *Ph.Int.* dissolusiemetode nie.

Moontlike redes vir die swak dissolusie (wanneer die *Ph.Int.* metode gebruik is) is geïdentifiseer en ondersoek. Ondersoek na die oplosbaarheid van kiniensulfaat, het bevind dat die *Ph.Int.* dissolusiemetode se vereistes te streng is, aangesien gevind is dat die oplosbaarheid van kiniensulfaat in fosfaatbuffer pH 6.8 (dissolusiedium gespesifiseer deur die *Ph.Int.*) baie minder is as in suur media (soos voorgestel deur die BP en USP dissolusiemetodes). Verskeie aangepaste dissolusiemetodes (genaamd ontwikkelingstudies) is ondersoek om te dien as potensiële alternatiewe vir die *Ph.Int.* dissolusiemetode. Die ontwikkelingstudies het 'n alternatiewe dissolusiedium, agitasiesnelhede (50 rpm, 75 rpm, 100 rpm) en volumes van die medium (500 ml, 750 ml, 900 ml en 1000 ml) ondersoek. Ontwikkelingstudie 6 is as 'n alternatiewe dissolusiemetode voorgestel. Ontwikkelingstudie 6 bepaal die gebruik van dieselfde medium as die oorspronklike *Ph.Int.* metode, aangesien dit weens die diskriminasievermoë daarvan as die voorkeurmedium geag word. Om die belemmerde oplosbaarheid van kiniensulfaat in fosfaatbuffer aan te spreek, is die volume van die medium en agitasie (met verwysing na die oorspronklike metode) tot 900 ml en 100 rpm onderskeidelik verhoog. Dieselfde analitiese kwantifiseringstegniek (UV-Vis spektroskopie) word voorgestel vir Ontwikkelingstudie 6. Hierdie nuut voorgestelde metode verskaf finale uitkomst wat vergelyk kan word met dié van die USP and BP, alhoewel dit meer diskriminerend is as die USP en BP.

Sleutelwoorde: kiniensulfaattablette, dissolusie, malaria, farmakopeë, gevalideerde analitiese metodes, harmonisering

Aims and Objectives

The following was considered the objectives for this study:

To conduct a literature review of malaria, how to effectively prevent and treat it and how the quality of medicine affect effective treatment thereof. It was found that the presence of poor quality anti-malarial medicine on the market (with African countries mostly affected) contributed to a large number of malaria deaths. Counterfeit or substandard variations of quinine sulfate were found to be among some of the medications reported to be available on the market. When tested by independent laboratories, quinine sulfate tablets presented with poor quality dissolution results. A summary is given on what analytical tests are deemed necessary to confirm the quality of medicine and to prove its quality, safety and efficacy. Analytical quality control procedures and specifications of quinine sulfate tablets, set by three international monographs were evaluated. **(Chapter 1)**.

To conduct a literature review of the history, chemical, pharmaceutical and pharmacological properties of quinine sulfate **(Chapter 2)**.

To obtain an understanding of the analytical principles/techniques required to successfully complete quality testing and analysis of quinine sulfate tablets in a laboratory. To ensure that the correct grade of materials was sourced for testing and to ensure that equipment was set up and maintained in accordance with GLP requirements **(Chapter 3)**.

To investigate the validation parameters considered in the process of monograph validation. To investigate which of these parameters are necessary to be repeated and confirmed when method verification is performed in a quality control laboratory. To ensure that the methods still perform as intended (fit for its purpose) as when it were validated at the original developing laboratory **(Chapter 4)**.

To compare the results obtained from conducting quality analyses as prescribed by the three different monographs (*Ph.Int.*, USP and BP). When the final outcome of results is similar this might indicate interchange ability (the possibility of harmonisation) of analytical tests prescribed by the three monographs **(Chapter 5)**.

To investigate the factors influencing the dissolution behaviour of solid oral dosage forms at certain dissolution conditions. To perform dissolution tests to investigate if discrepancies between the methods prescribed by the three different monographs (*Ph.Int.*, USP and BP) exist. To obtain a dissolution method as close as possible to the ideal dissolution test. The ideal dissolution test is able to discriminate between different formulations without failing quinine

sulfate tablets of good quality. If necessary, to propose a dissolution method most suitable for the dissolution testing of quinine sulfate tablets (**Chapter 6**).

Table of Contents

Acknowledgements	i
Abstract	ii
Uittreksel	iv
Aims and Objectives	vi
Chapter 1: The importance of quality anti-malarial treatment	1
1.1 Introduction to malaria	1
1.1.1 Prevalence and transmission	1
1.1.2 Parasitology	3
1.1.3 Pathophysiology and clinical manifestations of malaria	4
1.1.4 Diagnosis of malaria	5
1.1.5 Prevention and treatment.....	5
1.2 The impact of - and means to combat poor quality medicine	5
1.3 Medicine regulations	6
1.3.1 Good Manufacturing Practice (GMP)	7
1.3.2 Analytical quality control (QC) testing	7
1.3.2.1 Identification	8
1.3.2.2 Assay.....	9
1.3.2.3 Uniformity of dosage units	9
1.3.2.4 Impurities or related substances	9
1.3.2.5 Disintegration.....	9
1.3.2.6 Dissolution	10
1.3.3 The suitability of QC analytical procedures and specifications	10

Chapter 2: An overview of Quinine Sulfate.....	13
2.1 Chemical, pharmaceutical and pharmacological properties of quinine	14
2.1.1 Classification of quinine	14
2.1.2 Extraction of quinine	14
2.1.3 Synthesis of quinine.....	15
2.1.4 Chemical properties of quinine sulfate	15
2.1.5 Commercially available dosage forms of quinine sulfate	15
2.1.6 Solubility	16
2.2 Pharmacology	17
2.2.1 Indications	17
2.2.2 Pharmacokinetic properties.....	17
2.2.3 Mechanism of action.....	17
2.2.4 Indicated treatment dosage.....	18
2.2.5 Side effects.....	18
2.2.6 Interactions	18
2.2.7 Contra-indications.....	18
2.2.8 Safety and toxicity.....	19
2.2.9 Failure of quinine treatment	19
2.2.10 Resistance to quinine.....	19
Chapter 3: Materials, methods, techniques and equipment	20
3.1 Wet chemistry techniques/principles	21
3.1.1 Fluorescence	21
3.1.2 Precipitation reactions.....	23

3.1.3	Measuring pH for identification purposes	24
3.1.4	Thin Layer Chromatography (TLC)	26
3.1.5	Non-aqueous titration.....	29
3.2	Disintegration.....	30
3.3	Dissolution	32
3.3.1	Dissolution of the API in the dissolution medium.....	32
3.3.2	Dissolution Apparatus.....	34
3.3.2.1	Rotating Basket Method (Apparatus 1)	36
3.3.2.2	Paddle Method (Apparatus 2)	37
3.4	Ultraviolet-Visible (UV-Vis) Spectrophotometry	39
3.5	High Performance Liquid Chromatography (HPLC)	41
3.6	Uniformity of dosage units.....	44
3.7	Non-compendial procedures	47
3.7.1	Solubility experiments.....	47
3.8	Quinine sulfate tablet samples and reference standards	48
Chapter 4: Verification of compendial methods.....		50
4.1	Method validation	50
4.1.1	Terminology: validation parameters	51
4.1.1.1	Accuracy.....	52
4.1.1.2	Precision.....	52
4.1.1.3	Specificity	52
4.1.1.4	Limit of detection.....	53
4.1.1.5	Quantitation limit.....	53

4.1.1.6	Linearity and range	54
4.1.1.7	Robustness.....	54
4.2	Verification of analytical methods	54
4.3	Verification of the quinine sulfate tablet monograph methods	55
4.3.1	Verification of the dissolution method specified in the International Pharmacopoeia for quinine sulfate tablets	56
4.3.1.1	Specificity	56
4.3.1.2	Linearity and range	58
4.3.1.3	Precision and repeatability	60
4.3.1.4	Accuracy/recovery	61
4.3.2	Method verification of the dissolution method specified in the United States Pharmacopoeia for quinine sulfate tablets	61
4.3.2.1	Specificity	62
4.3.2.2	Linearity and range	64
4.3.2.3	Precision and Repeatability.....	66
4.3.2.4	Accuracy/recovery	67
4.3.3	Method verification of the dissolution method specified in the British Pharmacopoeia for quinine sulfate tablets	67
4.3.3.1	Specificity	68
4.3.3.2	Linearity and range	70
4.3.3.3	Precision and repeatability	72
4.3.3.4	Accuracy/recovery	73
4.3.4	Method validation of the dissolution method using acetate buffer with a pH of 4.5 as dissolution medium	73
4.3.4.1	Specificity	74

4.3.4.2	Linearity and range	76
4.3.4.3	Precision and repeatability	78
4.3.4.4	Accuracy/recovery	79
4.3.5	Method verification of the non-aqueous titration assay method as specified by the International Pharmacopoeia and British Pharmacopoeia for quinine sulfate tablets.....	79
4.3.5.1	Specificity	82
4.3.5.2	Linearity and range	82
4.3.5.3	Precision and repeatability	84
4.3.5.4	Accuracy/recovery	85
4.3.6	Method verification of the HPLC assay method as specified by the United States Pharmacopoeia.....	85
4.3.6.1	Specificity	86
4.3.6.2	Linearity and range	90
4.3.6.3	Precision and repeatability	93
4.3.6.4	Accuracy/recovery	94
4.3.7	Verification of the method testing related cinchona alkaloids/other cinchona alkaloids as specified by the International Pharmacopoeia and British Pharmacopoeia.....	94
4.3.7.1	Specificity	98
4.3.7.2	Linearity and range	103
4.3.7.3	Precision and repeatability	106
4.3.7.4	Accuracy/recovery	106
Chapter 5: Identification, Assay and Related Substances		108
5.1	Identification	109

5.1.1	Fluorescence	109
5.1.2	Precipitation reactions.....	110
5.1.3	Measuring pH	113
5.1.4	Ultraviolet spectrophotometry	116
5.1.5	Thin Layer Chromatography (TLC)	117
5.1.5.1	The BP monograph TLC method:	117
5.1.5.2	The <i>Ph.Int.</i> monograph TLC method (A.1):	120
5.1.5.3	The USP monograph TLC method:.....	123
5.1.6	High performance chromatography (HPLC)	125
5.2	Consistency of API content in dosage units.....	125
5.3	Assay of quinine sulfate in quinine sulfate tablets	128
5.3.1	HPLC as method of analysis - USP monograph.....	128
5.3.1.1	Experimental Procedure	128
5.3.1.2	Results	129
5.3.2	Non-aqueous titration as method of analysis - BP and <i>Ph.Int.</i> method.....	134
5.3.2.1	Experimental procedure.....	134
5.3.2.2	Results	134
5.3.3	Comparison between the assay results by means of a <i>t</i> -test assuming equal variances	135
5.4	Other/Related cinchona alkaloids.....	136
5.4.1	HPLC as method of analysis - BP and <i>Ph.Int.</i> monograph.....	136
5.4.1.1	Experimental procedure.....	136
5.4.1.2	Results	137

5.4.2	TLC analysis.....	142
5.4.2.1	Correlation between the HPLC (<i>Ph.Int.</i> monograph) and TLC (USP monograph) results for related substances/other cinchona alkaloids	144
5.5	Identification by means of HPLC analysis	145
Chapter 6: API release – Dissolution and disintegration.....		148
6.1	Dissolution requirements/specifications of the USP, BP and <i>Ph.Int.</i> monographs for quinine sulfate tablets	149
6.2	Results and discussion for the dissolution and disintegration testing according to the specified pharmacopoeias.....	150
6.2.1	Disintegration.....	150
6.2.2	Dissolution	151
6.3	Dissolution profiles (from pharmacopoeial dissolution methods).....	153
6.4	The Noyes-Whitney equation and dissolution rate	159
6.5	Solubility and the Biopharmaceutics Classification System (BCS)	160
6.6	Dissolution of quinine sulfate under varying conditions.....	164
6.6.1	Developmental study 1	165
6.6.2	Developmental study 2	167
6.6.3	Developmental study 3	169
6.6.4	Developmental study 4	171
6.6.5	Developmental study 5	173
6.6.6	Developmental study 6	175
6.7	Acceptance criteria.....	180
6.8	Additional considerations	181
Chapter 7: Summary and conclusion.....		185

Annexure A 196
Annexure B 197
Annexure C 198
Annexure D 199
Bibliography 200

List of Tables

Table 1-1:	The difference between counterfeit and substandard medicines (adapted from Obi-Eyisi & Wertheimer, 2012:2 and WHO, 2003).....	6
Table 1-2:	Summary of the differences in dissolution procedures and specifications pertaining to quinine sulfate tablets (adapted from quinine sulfate tablet monographs of the USP, BP and <i>Ph.Int.</i>).....	11
Table 3-1:	Summary of analytical QC tests for the quinine sulfate tablet monographs of the USP, BP and <i>Ph.Int.</i> (USP, 2013 ; BP, 2013 ; <i>Ph.Int.</i> , 2013).....	20
Table 3-2:	List of equipment used for the USP monograph fluorescence test.....	22
Table 3-3:	List of reagents used for the USP fluorescence test	22
Table 3-4:	List of equipment used for test for sulfates	24
Table 3-5:	List of reagents used for test for sulfates	24
Table 3-6:	List of equipment used for pH identification testing.....	25
Table 3-7:	List of reagents used for pH identification testing	25
Table 3-8:	A list of common solvents with increasing polarity (Watson, 2005:320)	27
Table 3-9:	List of equipment used for analysis by means of TLC	28
Table 3-10:	List of reagents used for analysis by means of TLC	29
Table 3-11:	List of equipment used for assay analysis by means of non-aqueous titration	30
Table 3-12:	List of reagents used for assay analysis by means of non-aqueous titration	30
Table 3-13:	List of equipment used for disintegration testing.....	32
Table 3-14:	List of reagents used for disintegration testing	32
Table 3-15:	List of equipment used for dissolution testing	38
Table 3-16:	List of reagents used for dissolution testing.....	38

Table 3-17:	List of equipment used for tests requiring UV-Visible Spectrophotometry.....	41
Table 3-18:	List of reagents used for tests requiring UV-Visible Spectrophotometry	41
Table 3-19:	Classification of high performance liquid chromatographic techniques (Watson, 2005:270).....	43
Table 3-20:	List of equipment used for assay, related cinchona alkaloids and identification testing by means of HPLC analysis	43
Table 3-21:	List of reagents used for assay, related cinchona alkaloids and identification testing by means of HPLC analysis	44
Table 3-22:	List of equipment used for uniformity of mass/weight variation	46
Table 3-23:	List of equipment used for solubility testing	47
Table 3-24:	List of reagents used for solubility testing	48
Table 3-25:	Description of the quinine sulfate tablet products used in this study	48
Table 4-1:	Validation parameters considered during analytical method validation (ICH, 2005)	51
Table 4-2:	Parameters that were considered during method verification of the quantitative tests for this study	55
Table 4-3:	Compendial methods which were verified for the purpose of this study	56
Table 4-4:	Preparation of the different concentrations of quinine sulfate solution used for the linear regression analysis of the method verification of the dissolution method specified in the Ph.Int.....	58
Table 4-5:	Solution concentrations and range used during the linear regression analysis and analytical results obtained (<i>Ph.Int.</i> dissolution method verification).....	59
Table 4-6:	Preparation of the different concentrations of quinine sulfate solution used for the linear regression analysis of the method verification of the dissolution method specified in the USP	64

Table 4-7:	Solution concentrations and range used during the linear regression analysis and analytical results obtained (USP dissolution method verification).....	65
Table 4-8:	Preparation of the different concentrations of quinine sulfate solution used for the linear regression analysis of the method verification of the dissolution method specified in the BP	70
Table 4-9:	Solution concentrations and range used during the linear regression analysis and analytical results obtained (BP dissolution method verification).....	71
Table 4-10:	Preparation of the different concentrations of quinine sulfate solution used for the linear regression analysis of the preliminary method validation of the dissolution method considered with acetate buffer as dissolution medium	76
Table 4-11:	Solution concentrations and range used during the linear regression analysis and analytical results obtained (Acetate buffer, pH 4.5 dissolution method preliminary validation)	77
Table 4-12:	Comparison between non-aqueous titration methods of the BP and <i>Ph.Int.</i> for quinine sulfate tablets	80
Table 4-13:	Solution concentrations and range used during the linear regression analysis and analytical results obtained (non-aqueous titration method verification) of quinine sulfate	83
Table 4-14:	Summary of the preparation of the different concentrations of quinine sulfate solutions used for the linear regression analysis of the assay method verification	91
Table 4-15:	Concentrations of solutions and range of the linear regression analysis (USP assay method verification)	92
Table 4-16:	The main conditions of the related/other cinchona alkaloid methods of the BP and <i>Ph.Int.</i>	95
Table 4-17:	Relative retention times specified by the <i>Ph.Int.</i> monograph compared to the experimental relative retention times obtained.....	100

Table 4-18:	Summary of the preparation of the different concentrations of quinine sulfate solutions used for the linear regression analysis of the HPLC procedure for related cinchona alkaloids method verification.....	104
Table 4-19:	Concentrations and range of the linear regression analysis (<i>Ph.Int.</i> test for cinchona alkaloids method verification)	105
Table 5-1:	Analytical QC tests for the quinine sulfate tablet monographs of the USP, BP and <i>Ph.Int.</i> (pertaining to Chapter 5)	108
Table 5-2:	The outcomes of the fluorescence test.....	110
Table 5-3:	A summary of the procedures for the test for sulfates utilised by the various pharmacopoeia	111
Table 5-4:	Outcomes for the test for sulfates.....	113
Table 5-5:	Identification by means of pH utilised by the BP and <i>Ph.Int.</i>	114
Table 5-6:	The pH of the quinine sulfate suspensions according to the test procedures of the <i>Ph.Int.</i> and BP	115
Table 5-7:	Outcome for the UV-Vis identification test	116
Table 5-8:	R _F -values of the quinine sulfate spots present in standard and sample solutions for identification purposes - BP monograph.....	119
Table 5-9:	R _F -values of the quinine sulfate spots present in standard and sample solutions for identification purposes - <i>Ph.Int.</i> monograph	122
Table 5-10:	R _F -values of the quinine sulfate spots present in standard and sample solutions for identification purposes.....	125
Table 5-11:	Uniformity of mass results according to the <i>Ph.Int.</i> general requirements...	126
Table 5-12:	Weight variation results according to the BP general requirements for consistency of dosage units	127
Table 5-13:	Assay results for quinine sulfate Products 1 - 4 obtained by HPLC analysis.....	133
Table 5-14:	Assay results obtained for Products 1 - 4 by non-aqueous titration analysis.....	135

Table 5-15:	Statistical comparison between the assay results from HPLC and non-aqueous titration.....	136
Table 5-16:	The results obtained when testing for related cinchona alkaloids present in quinine sulfate tablets - <i>Ph.Int.</i> monograph.....	138
Table 5-17:	Related substances results from the <i>Ph.Int.</i> monograph HPLC method and the USP monograph TLC method	144
Table 6-1:	The dissolution acceptance criteria specified in the general chapters of the USP, BP and <i>Ph.Int.</i> (USP, 2013; BP, 2013 and <i>Ph.Int.</i> , 2013)	149
Table 6-2:	Dissolution conditions, specifications and procedures as required by the different pharmacopoeia for quinine sulfate tablets (USP, 2013; BP, 2013 and <i>Ph.Int.</i> , 2013).....	150
Table 6-3:	Disintegration testing results for Products 1 - 4 as specified in the <i>Ph.Int.</i> monograph for quinine sulfate tablets.....	151
Table 6-4:	Dissolution results of Products 1 - 4 using the dissolution procedures of the BP, USP and <i>Ph.Int.</i> monographs	152
Table 6-5:	Multiple-point dissolution results for Products 1 - 4 using the BP monograph dissolution conditions (n = 12)	154
Table 6-6:	Multiple-point dissolution results for Products 1 - 4 using the USP monograph dissolution conditions (n = 12)	155
Table 6-7:	Multiple-point dissolution results for Products 1 - 4 using the <i>Ph.Int.</i> monograph dissolution conditions (n = 12)	156
Table 6-8:	Similarity (f_2) calculations for the different dissolution profile comparisons obtained from performing the dissolution methods obtained in the BP, USP and <i>Ph.Int.</i> monograph.....	158
Table 6-9:	The Biopharmaceutics Classification System (Shargel <i>et al.</i> , 2005:483)	160
Table 6-10:	Solubility of quinine sulfate as reported by Strauch <i>et al.</i> (2011:501) with the appropriate calculated D/S ratios.....	161
Table 6-11:	Solubility of quinine sulfate in different media over the pH range of 1.2 - 6.8 at $37 \pm 0.5^\circ\text{C}$ with the calculated appropriate D/S ratios	162

Table 6-12:	Summary of the dissolution conditions considered for the developmental studies	165
Table 6-13:	Multiple-point dissolution results for Products 1 - 4 using the Developmental study 1 dissolution conditions (acetate buffer pH 4.5, 900 ml, 75 rpm, paddle) (n = 6)	166
Table 6-14:	Multiple-point dissolution results for Products 1 - 4 using the Developmental study 2 dissolution conditions (acetate buffer pH 4.5, 500 ml, 75 rpm, paddle) (n = 6)	167
Table 6-15:	Multiple-point dissolution results for Products 1 - 2 using the Developmental study 3 dissolution conditions (acetate buffer pH 4.5, 500 ml, 50 rpm, paddle) (n = 6)	169
Table 6-16:	Multiple-point dissolution results for Products 1 - 4 using the Developmental study 4 dissolution conditions (phosphate buffer pH 6.8, 900 ml, 75 rpm) (n = 12).....	171
Table 6-17:	The f_2 -values calculated for the Developmental study 4 with reference to the original <i>Ph.Int.</i> method dissolution results	172
Table 6-18:	Comparison of the outcomes of Developmental study 4 and original <i>Ph.Int.</i> monograph conditions between the four products	173
Table 6-19:	Multiple-point dissolution results for Products 1 - 2 using the Developmental study 5 dissolution conditions (phosphate buffer pH 6.8, 1000 ml, 75 rpm) (n = 6).....	174
Table 6-20:	The f_2 -values calculated for the Developmental study 4 with reference to the Developmental study 5 of Products 1 and 2	175
Table 6-21:	Multiple-point dissolution results for Products 1 - 4 using the Developmental study 6 dissolution conditions (phosphate buffer pH 6.8, 900 ml, 100 rpm) (n = 12).....	175
Table 6-22:	The f_2 -values calculated for the different Developmental dissolution results with reference to the USP, BP and <i>Ph.Int.</i> monographs dissolution results.....	177

Table 6-23:	Comparison between the dissolution methods and specifications of Developmental study 6 and the original <i>Ph.Int.</i> method for quinine sulfate tablets.....	181
Table 6-24:	The proposed changes for consideration for the replacement of the current dissolution method for quinine sulfate tablets of the Ph.Int monograph as well as wording proposed for the replacement of the current <i>Ph.Int.</i> monograph dissolution test	182
Table 7-1:	Summary of analytical QC tests for the quinine sulfate tablets monographs of the USP, BP and <i>Ph.Int.</i>	186
Table 7-2:	Summary of the method verification parameters that were evaluated and discussed in Chapter 4.....	187
Table 7-3:	Summary of ID, assay and related substance test results	188
Table 7-4:	The different developmental phase dissolution parameters that were proposed for the study.....	190
Table 7-5:	Summary of the outcomes of the Developmental studies	191

List of Figures

Figure 1-1:	Malaria-endemic countries in the Eastern Hemisphere (Arguin & Mali, 2012).....	2
Figure 1-2:	Malaria-endemic countries in the Western Hemisphere (Arguin & Mali, 2012).....	3
Figure 1-3:	The life cycle of the malaria parasite showing target areas for anti-malarial treatment action (Harvey <i>et al.</i> , 2000:350).	4
Figure 1-4:	An overview and rationale of the pharmacopoeia tests that apply to solid oral dosage forms.	10
Figure 2-1:	Photographs of the Cinchona tree (left), Cinchona bark (middle) and powdered Cinchona bark (right) (Sarah, 2010).....	13
Figure 2-2:	Structure of Quinine sulfate (USP, 2012).....	14
Figure 2-3:	Examples of FPP containing quinine;(A) Quinine sulfate 300 mg tablets, (B) Quinine dihydrochloride ampoules for injection and (C) Quinine sulfate capsules 324 mg (RxResource.org, 2013 ; Wu Han Grand Pharmaceutical Group Co. Ltd., 2013 ; Reliable Canada).	16
Figure 3-1:	Visual presentation of the fluorescent properties of quinine sulfate (Willard <i>et al.</i> , 1981:107). Quinine fluorescence can be seen on the right and when hydrochloric acid is added the fluorescence disappear as seen on the left.....	22
Figure 3-2:	An example of a TLC plate, where S is the distance travelled by the mobile phase, 'A' is compound A with travel distance a, and 'B' is compound B with travel distance b (Watson, 2005:318).	26
Figure 3-3:	Chromatographic chamber and TLC sprayer (Watson, 2005:317).	27
Figure 3-4:	The surface of silica gel (Watson, 2005:318).	27
Figure 3-5:	An example of a disintegration apparatus for the testing of tablet disintegration (Alderborn, 2007:462 ; RIIP [®] /CENQAM [®]).	31
Figure 3-6:	Dissolution of a solid particle in a solvent (Shargel <i>et al.</i> , 2005:415).	34

Figure 3-7:	An example of a dissolution apparatus with: (1) Control panel, (2) Parameter readout screen, (3) Drive motor, (4) Stainless steel shaft, (5) Water bath, (6) Glass dissolution vessel, (7) Waterbath and Vessel Support framework, (8) Free-standing heater.....	35
Figure 3-8:	A graphical illustration of the rotating basket assembly and the technical requirements as required by the BP and USP (Alderborn, 2007:464).....	36
Figure 3-9:	A graphical illustration of the rotating paddle assembly and the technical requirement thereof as required by the USP (Alderborn, 2007:465).	37
Figure 3-10:	An example of absorbance spectra of hydrocortisone and betamethasone (Watson, 2005:89).	40
Figure 3-11:	Example how different compounds are retained during HPLC analysis (Watson, 2005:222).....	42
Figure 3-12:	Example of a chromatogram where the retention time (t_r) is used for identification purposes and the area under the peak for qualitative analysis (Watson, 2005:223).....	42
Figure 3-13:	Summary of the evaluation of consistency of dosage units as specified by USP, BP and <i>Ph.Int.</i>	46
Figure 4-1:	The UV absorbance spectra of quinine sulfate reference standard solution and each quinine sulfate sample solution (prepared using Products 1 - 4) phosphate buffer, pH 6.8 as solvent in accordance with the <i>Ph.Int.</i>	57
Figure 4-2:	Linear regression analysis for the <i>Ph.Int.</i> monograph for dissolution testing of quinine sulfate tablet method verification. The dashed line illustrates the calculated 95 % confidence interval for the linear regression.	60
Figure 4-3:	The UV absorbance spectra of quinine sulfate reference standard solution and each quinine sulfate sample solution (prepared using Products 1 -4) prepared using 0.01 M hydrochloric acid as solvent in accordance with the USP.	63

Figure 4-4:	Linear regression analysis for the USP monograph for dissolution testing of quinine sulfate tablets method verification. The dashed line illustrates the calculated 95% confidence interval for the linear regression.	66
Figure 4-5:	The UV-absorbance spectra of quinine sulfate reference standard solution and each sample solution prepared (prepared using Products 1 - 4) using 0.1 M hydrochloric acid as solvent in accordance with the BP.	69
Figure 4-6:	Linear regression analysis for the BP monograph for dissolution testing of quinine sulfate tablets method verification. The dashed line illustrates the calculated 95% confidence interval for the linear regression.	72
Figure 4-7:	The UV absorbance spectra of quinine sulfate reference standard solution and each quinine sulfate sample solution (prepared using Products 1 - 4) prepared using acetate buffer, pH 4.5 as solvent.	75
Figure 4-8:	Linear regression analysis for the developmental study using acetate buffer, pH 4.5 for dissolution testing of quinine sulfate tablets preliminary method validation.	78
Figure 4-9:	Standardisation of 0.1 N perchloric acid showing the reaction between the potassium hydrogen phthalate and the perchloric acid (Kar, 2005:109).....	82
Figure 4-10:	Linear regression analysis for the BP monograph for the assay of quinine sulfate tablets method verification. The dashed line illustrates the calculated 95% confidence interval for the linear regression.	84
Figure 4-11:	Example of a chromatogram of the mobile phase.....	88
Figure 4-12:	Example of a chromatogram of the system suitability solution.....	89
Figure 4-13:	Example of a chromatogram of the standard solution.....	89
Figure 4-14:	Example of the chromatograms obtained from the sample solutions of Product 1, 2, 3 and 4.....	90
Figure 4-15:	Linear regression analysis for the USP monograph for assay testing of quinine sulfate tablet method verification. The dashed line illustrates the calculated 95% confidence interval for the linear regression.	93

Figure 4-16:	Cinchona alkaloids specified in the <i>Ph.Int.</i> monograph for quinine sulfate tablets include: (a) cinchonidine, (b) quinine, (c) dihydroquinine, (d) quinidine and (e) dihydroquinidine (Moffat <i>et al.</i> , 2011).	97
Figure 4-17:	Example of a chromatogram of the mobile phase.....	101
Figure 4-18:	Example of a chromatogram of the solvent.	101
Figure 4-19:	Example of a chromatogram of the resolution solution (solution 3).....	102
Figure 4-20:	Example of a chromatogram of the 100% standard (solution 2).	102
Figure 4-21:	Sample chromatograms of each of the four products (solution 1).	103
Figure 4-22:	Linear regression analysis for the <i>Ph.Int.</i> monograph for testing of related cinchona alkaloids method verification. The dashed line illustrates the calculated 95% confidence interval for the linear regression	105
Figure 5-1:	A typical example depicting the fluorescent ability of quinine sulfate in sulphuric acid solution (left) which is quenched by the addition of hydrochloric acid (right).	110
Figure 5-2:	An example of the test for sulfates employed by the BP. A clear quinine sulfate aqueous solution (1) formed a white precipitate (2) when the barium chloride was added, a yellow/brown suspension when iodine was added (3) and when stannous chloride was added dropwise (4) to the solution it decolourised to the milky suspension again (5).	112
Figure 5-3:	The residue that formed after the solutions were evaporated to dryness (Product 1, (1), Product 2 (2), Product 3 (3) and Product 4 (4)).	115
Figure 5-4:	The UV absorbance spectra of the four different products a) Product 1, b) Product 2, c) Product 3 and d) Product 4	117
Figure 5-5:	Demonstration (from left to right) of how the TLC plate was spotted, developed in a chromatographic chamber and sprayed for detection.	119
Figure 5-6:	TLC plate where (a) represents the spot for quinine sulfate, (b) represents the spot for quinidine sulfate and (c) represents the spot for quinine sulfate present in the products - BP monograph	120

Figure 5-7:	TLC plate where (a) represents the spot for quinine sulfate, (b) represents the spot for quinidine sulfate and (c) represents the spot for quinine sulfate present in the various samples of the products using the <i>Ph.Int.</i> method.....	122
Figure 5-8:	TLC plate after being sprayed with glacial acetic acid, where (a) represents the spot for quinine present in the samples of the products, (b) represents the spot for cinchonidine present in the products, (c) represents the spot of the quinine present in solution A and (d) represents the spot for cinchonidine in solution B - USP method.....	124
Figure 5-9:	Example of a chromatogram of the mobile phase/solvent	130
Figure 5-10:	Example of a chromatogram of the system suitability solution.	130
Figure 5-11:	Example of a chromatogram of the standard solution.....	131
Figure 5-12:	Example of a chromatogram of Product 1.	131
Figure 5-13:	Example of a chromatogram of Product 2.	132
Figure 5-14:	Example of a chromatogram of Product 3.	132
Figure 5-15:	Example of a chromatogram of Product 4.	133
Figure 5-16:	Example of a chromatogram of the mobile phase.....	138
Figure 5-17:	Example of a chromatogram of the solvent.	139
Figure 5-18:	Example of a chromatogram of the resolution solution (solution 3).....	139
Figure 5-19:	Example of a chromatogram of the 100% standard solution (solution 2). ...	140
Figure 5-20:	Example of a chromatogram of Product 1 (solution 1).	140
Figure 5-21:	Example of a chromatogram of Product 2 (solution 1).	141
Figure 5-22:	Example of a chromatogram of Product 3 (solution 1).	141
Figure 5-23:	Example of a chromatogram of Product 4 (solution 1).	142
Figure 5-24:	The TLC plate after sprayed with glacial acetic acid (left). The TLC plate after sprayed with potassium iodoplatinate spray reagent (right) where	

(a) represents the spot for quinine present in the samples, (b) represents the spot for cinchonidine present in the samples, (c) represents the spot of the quinine present in standard solution A and (d) represents the spot for cinchonidine in standard solution B. The individual spots were identified as seen in the insert on the right where cinchonidine is represented by the purple. 143

Figure 6-1:	Dissolution profiles for Products 1 - 4 using the BP monograph dissolution conditions.	154
Figure 6-2:	Dissolution profiles for Products 1 - 4 using the USP monograph dissolution conditions	155
Figure 6-3:	Multiple-point dissolution results for Products 1 - 4 using the <i>Ph.Int.</i> monograph dissolution conditions (n = 12)	156
Figure 6-4:	The pH-solubility profiles of quinine sulfate API as determined in this study and that reported by Strauch <i>et al.</i> (2012:501).....	163
Figure 6-5:	Dissolution profiles for Products 1 - 4 using the Developmental study 1 dissolution conditions (acetate buffer pH 4.5, 900 ml, 75 rpm, paddle).....	166
Figure 6-6:	Dissolution profiles for Products 1 - 4 using the Developmental study 2 dissolution conditions (acetate buffer pH 4.5, 500 ml, 75 rpm, paddle).....	168
Figure 6-7:	Dissolution profiles for Products 1 and 2 tested using the Developmental study 3 dissolution conditions (acetate buffer pH 4.5, 500 ml, 50 rpm).....	169
Figure 6-8:	Examples of the coning that occurred during the Developmental study 3 for (a) Product 1 and (b) Product 2.....	170
Figure 6-9:	Dissolution profiles for Products 1 - 4 using the Developmental study 4 dissolution conditions (phosphate buffer pH 6.8, 900 ml, 75 rpm).....	172
Figure 6-10:	Dissolution profiles for Products 1 - 4 using the Developmental study 5 dissolution conditions (phosphate buffer pH 6.8, 1000 ml, 75 rpm).....	174
Figure 6-11:	Dissolution profiles for Products 1 - 4 using the Developmental study 6 dissolution conditions (phosphate buffer pH 6.8, 900 ml, 100 rpm).....	176

Figure 6-12:	Dissolution profiles for Product 1 (from the dissolution method of the USP monograph, BP monograph, <i>Ph.Int.</i> monograph, Developmental study 4, and Developmental study 6).	178
Figure 6-13:	Dissolution profiles for Product 2 (from the dissolution method of the USP monograph, BP monograph, <i>Ph.Int.</i> monograph, Developmental study 4, and Developmental study 6).	178
Figure 6-14:	Dissolution profiles for Product 3 (from the dissolution method of the USP monograph, BP monograph, <i>Ph.Int.</i> monograph, Developmental study 4, and Developmental study 6).	179
Figure 6-15:	Dissolution profiles for Product 4 (from the dissolution method of the USP monograph, BP monograph, <i>Ph.Int.</i> monograph, Developmental study 4, and Developmental study 6).	179
Figure 7-1:	Schematic outline of this study	185
Figure 7-2:	The dissolution profiles of the USP, BP and <i>Ph.Int.</i> quinine sulfate tablet monographs	192
Figure 7-3:	The dissolution profiles of Developmental study 1,2 and 3.	193
Figure 7-4:	The dissolution profiles of the Developmental study 4, 5 and 6.	194